Company Overview: Lepu Biopharma (2157.HK) Industry Focus - The company operates in the biopharmaceutical industry, specifically focusing on oncology treatments, including immunotherapy, antibody-drug conjugates (ADC), and oncolytic virus therapies [1][2]. Key Points and Arguments R&D Pipeline and Product Development - Lepu Biopharma has developed a comprehensive pipeline of oncology products, covering three major areas: immunotherapy, ADC targeted therapy, and oncolytic virus drugs. The pipeline includes: - Already marketed PD-1 monoclonal antibody, Putilizumab, and MRG003 - Six ADC drugs, one introduced oncolytic virus, and one T cell engager (TCE) drug currently in clinical stages - The company is expected to enter a phase of new drug approvals over the next 3-5 years, indicating a robust pipeline [1][2]. Financial Performance - The company has achieved steady revenue growth driven by business development (BD) and sales, with a stable expense structure. - In the first half of 2025, Lepu Biopharma reported its first profit and positive operating cash flow [2]. Competitive Advantages of ADCs - MRG003 (EGFR ADC) has been approved for use in late-line nasopharyngeal carcinoma (NPC) in China, demonstrating superior survival benefits and safety compared to competitors. The drug is also being positioned for broader indications in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) [2][3]. - MRG004A (TF-ADC) for late-line pancreatic cancer has shown strong competitive potential and is currently in Phase III trials [2][3]. - MRG006A (GPC3 ADC) targets the liver cancer market and has shown promising results in Phase I trials, with plans to initiate Phase III trials in 2026 [3]. Oncolytic Virus Therapy - The company introduced the oncolytic virus therapy CG0070 in 2019, targeting the bladder cancer market. - CG0070 has initiated a rolling Biologics License Application (BLA) with the FDA for high-risk non-muscle invasive bladder cancer (NMIBC) and is undergoing critical registration bridging trials in China. The therapy has demonstrated the best historical durability of efficacy data in the NMIBC field, with a G3+ treatment-related adverse event (TRAE) rate of 0 [3]. International Expansion - The company has made progress in international collaborations with MRG007 (CDH17 ADC) and CTM012 (a tri-antibody targeting CD3/4-1BB/DLL3), enhancing its tumor immunotherapy output [3]. Revenue Projections - Lepu Biopharma is still in the investment phase for new drug development, with projected revenues of 880 million, 1.02 billion, and 1.49 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 138%, 16%, and 47%. The net profit attributable to the parent company is projected to be -20 million, 10 million, and 280 million yuan for the same years [3]. Risks - Potential risks include: - Delays in clinical progress of innovative drugs - Clinical data not meeting expectations - Sales performance of newly launched drugs falling short - Geopolitical risks [4].